Dr. Wysham goes over the details of how the new SGLT2 compounds work, and talks about the benefits and disadvantages of these potential new agents, including previous concerns around bladder cancer with dapagliflozin, giving us an update on the latest news.
Dr. Carol Wysham is Adjunct Research Professor within the Department of Pharmacotherapy at Washington State University, Assistant Clinical Professor of Medicine at the University of Washington School of Medicine and is Section Head of the Department of Endocrinology at Rockwood Clinic in Spokane, Washington. Her current areas of research interest include reduction of CVD risk in type 2 diabetes and improving delivery of care for diabetes. She has been involved with numerous trials for the National Institute of Health including the ACCORD Trial and the AIM-High Trial.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2013 Diabetes In Control, Inc.. All rights reserved.
